Drug Pricing
Our work in Drug Pricing
-
Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection
Improved treatment options and better early detection have led to significant survival gains for cancer patients diagnosed from 1997 to 2007, generating considerable social value over this time period.
Categorized in -
The Impact of Delayed Hepatitis C Viral Load Suppression on Patient Risk: Historical Evidence from the Veterans Administration
While the high cost of new hepatitis C treatments has resulted in “watchful waiting” strategies to safely delay treatment, this study found that this approach delays viral load suppression and negatively impacts patient risk for adverse events and death.
Categorized in -
Graduate Students Earn Top Awards at International Pharmacoeconomics Conference
USC students won awards for best student poster and best podium presentation.
Categorized in -
Value of Improved Lipid Control in Patients at High Risk for Adverse Cardiac Events
This study estimated the social value of reducing low-density lipoprotein cholesterol levels by 50% for patients in the two highest statin-benefit groups and found that PCSK9 inhibitors may have considerable net value depending on the prices payers ultimately select.
Categorized in -
Competing Risks: Investing in Sickness Rather Than Health
The authors contend that the time has come for the US to distance itself from the rhetoric and colored ribbons of conquering individual diseases to begin a real discussion about how best to help Americans achieve longer, healthier, and more productive lives.
Categorized in -
Estimating the Lifetime Price of Pharmaceuticals: What Are the Long-Term Costs to Society?
This study estimated the long-term average cost for a typical pharmaceutical accounting for the effects of generic competition and medical cost offsets, and found that reductions in price due to generic entry yield meaningful reductions in the average cost per prescription society pays over the lifetime of a drug, and that decisions to grant market access should consider these long-term costs to ensure patients have access to drugs that provide value.
Categorized in -
Does Patient Cost Sharing for HCV Drugs Make Sense?
Despite the high cost of novel hepatitis C treatments and patients’ apparent willingness to bear part of it, high patient cost sharing is both inefficient and inequitable. Modestly higher premiums for all beneficiaries can achieve the same financial goals for the insurer, without excessively burdening the sickest and least advantaged members of society.
Categorized in -
Value of Expanding HCV Screening and Treatment Policies in the United States
In investigating the value of expanding screening and treatment for hepatitis C virus infection in the US, the researchers found that, although increasing screening may generate some value to society, only when paired with expanded access to treatment at earlier disease stages will it produce considerable value.
Categorized in -
The Wider Public Health Value of HCV Treatment Accrued by Liver Transplant Recipients
This study describes the unique value created by treatments that spare organs from failure and thus conserve donated organs for transplant into others, using hepatitis C virus as a case study.
Categorized in -
Costs and Spillover Effects of Private Insurers’ Coverage of Hepatitis C Treatment
This study modeled hepatitis C virus disease progression and transmission to simulate the economic and social effects of different private-payer HCV treatment scenarios on Medicare.
Categorized in